1月8日，深圳市精锋医疗科技股份有限公司（简称：精锋医疗）于港交所挂牌上市，开盘精锋医疗涨36.45%，报59.00港元/股，市值228.76亿。 截至发稿，精锋医疗每股涨27.31%至55.05港元，总市值213.44亿。 | 今开 | 59.000 | | 最高 | 60.000 | | 成交量 | 1137万股 | | --- | --- | --- | --- | --- | --- | --- | --- | | 昨收 | 43.240 | | 最低 | 48.000 | | 成交额 | 6.36亿 | | 换手率 | 3.51% | | 市盈(TTM) | 亏损 | | 总市值 | 213.44亿 | | 分时 | 王日 | 日K | 周K | 目K | 季K | 年K | 更多v | 来源：百度股市通 此前，精锋医疗曾在2022年4月、2023年1月、2025年12月三次递表港交所，历经多轮打磨终获资本市场认可。 腾讯红杉都投了，资本阵容豪华 翻开精锋医疗的投资者名单，红杉中国、淡马锡、博裕资本、联想之星等赫然在列，此外，精锋医疗本次港股IPO还引入超十位基石投资者， 包括中东资本ADIA、UB ...

Group 1 - The company, Jingfeng Medical-B (02675), plans to conduct a global offering of 27.72 million H-shares from December 30, 2025, to January 5, 2026, with a share price of HKD 43.24 per share [1] - The company specializes in advanced surgical robots, having developed products for minimally invasive and non-invasive surgeries, including the multi-port and single-port laparoscopic surgical robots [1] - The company has reported a significant increase in revenue, from RMB 48 million for the year ending December 31, 2023, to RMB 160 million for the year ending December 31, 2024 [2] Group 2 - The company has incurred operating losses during the reporting periods, with net losses of RMB 213 million, RMB 218.5 million, RMB 133 million, and RMB 89.1 million for the respective periods due to R&D expenses [2] - The company has entered cornerstone investment agreements with several investors, including OrbiMed Genesis and Tencent, agreeing to subscribe for shares totaling USD 75 million under certain conditions [3] - The net proceeds from the global offering are expected to be approximately HKD 1.1166 billion, with allocations for R&D, commercialization, capacity expansion, and potential strategic acquisitions [4]

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as Precision Medical) has passed the listing hearing on the Hong Kong Stock Exchange, with Morgan Stanley and GF Securities as joint sponsors [1] Company Overview - Precision Medical is an advanced surgical robotics company in the medical device industry, focused on the design, development, and manufacturing of surgical robots. The company has three products at different stages of research and development, targeting the market potential of surgical robots, including multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and natural orifice surgical robots for minimally invasive procedures [3] Product Portfolio - The product lineup includes two core self-developed products: the Precision Multi-Port Laparoscopic Surgical Robot and the Precision Single-Port Laparoscopic Surgical Robot. Additionally, the company has the Precision Bronchoscopy Robot, which is not a core product. The Multi-Port Laparoscopic Surgical Robot is designed for minimally invasive surgeries across urology, gynecology, general surgery, and thoracic surgery, while the Single-Port Laparoscopic Surgical Robot is used for surgeries through a single small incision or natural orifice, applicable in urology, gynecology, and general surgery [3] Market and Regulatory Achievements - Precision Medical is the first company in China and the second globally to obtain regulatory approval for multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and natural orifice surgical robots. The company received its first registration approvals from the National Medical Products Administration for these products in December 2022, November 2023, and January 2025, respectively [4] Financial Performance - For the fiscal years ending June 30, 2023, and 2024, Precision Medical reported revenues of approximately RMB 48.04 million and RMB 160 million, respectively. The company incurred losses of approximately RMB 213 million and RMB 219 million for the same periods. The financial data indicates a significant investment in research and development, with R&D expenses of RMB 171.23 million and RMB 226.25 million for the respective years [4][7]